A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT04045028 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

41

Enrollment

INDUSTRY

Sponsor class

Stopped Slow recruitment

Conditions

Multiple Myeloma
Non-Hodgkin Lymphoma
B-Cell Lymphoma

Interventions

DRUG: Tiragolumab
DRUG: Daratumumab/rHuPH20
DRUG: Rituximab
DRUG: Atezolizumab

Sponsor

Genentech, Inc.